Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Phase I open-label, ascending dose trial of AGEN1884, an anti-CTLA-4 monoclonal antibody, in advanced solid malignancies: Dose selection for combination with PD-1 blockade.
PaperCitations, authors & open-access status
Phase I open-label, ascending dose trial of AGEN1884, an anti-CTLA-4 monoclonal antibody, in advanced solid malignancies: Dose selection for combination with PD-1 blockade. is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 2 citations, 2018 year and closed oa status.
2
Citations
2018
Year
closed
OA Status